NYX-2925

DB19149InvestigationalSmall molecule

NYX-2925 is under investigation in clinical trial NCT04146896 (Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)).

Mechanism: Pharmacologically active on NMDA receptor
Curator reviewed
Formula / weight: C₁₄H₂₃N₃O₄ · 297.355 g/mol (avg)
Also known as: (αS,4R)-α-[(1R)-1-Hydroxyethyl]-5-(2-methyl-1-oxopropyl)-1-oxo-2,5-diazaspiro[3.4]octane-2-acetamide · X062KF5ZV3
Code names: CS-0113907 · HY-135741 · NYX-2925

Resolves to

Compound

UNIIX062KF5ZV3CAS2012536-16-0ChEMBLCHEMBL5095189

Structure

InChIKeyNFXPEHLDVKVVKA-ISTVAULSSA-NSMILESC[C@@H](O)[C@H](N1C[C@]2(CCCN2C(=O)C(C)C)C1=O)C(N)=O

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which companies are running trials of NYX-2925, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account